Stocks making the biggest moves premarket: Boeing, Disney, Wynn Resorts, Altria, Zogenix & more

0
49

Spencer Platt | Getty Images
Traders work on the floor of the New York Stock Exchange on March 04, 2019 in New York City.

Check out the companies making headlines before the bell:

Fiat Chrysler Fiat Chrysler will pay $110 million to settle a lawsuit that it had misled investors about safety concerns surrounding excess diesel emissions. An investor group had sued the automaker in 2015, saying it had falsely claimed it was complying with safety regulations.

Wynn ResortsWynn is offering $7.1 billion for Australian casino operator Crown Resorts. Crown said talks between the two parties were at a preliminary stage, with the proposed bid consisting of 50% cash and 50% in Wynn shares.

Alcon Alcon will begin trading on the New York Stock Exchange today under the symbol “ALC,” following the Swiss eye care company’s spin-off from drugmaker Novartis.

Altria Altria has been asked by the Federal Trade Commission for more information on its investment in e-cigarette maker Juul. Altria, the maker of Marlboro cigarettes, bought a 35 percent stake in Juul for $12.8 billion in November, and is now seeking to convert its non-voting stake in Juul to voting shares.

SAPUBS downgraded the enterprise software maker’s stock to “neutral” from “buy,” saying it doesn’t foresee that the November acquisition of experience management company Qualtrics will transform SAP’s near-term prospects. UBS also feels that SAP’s gross margin targets may not be attainable.

PerkinElmer PerkinElmer was upgraded to “buy” from “neutral” at Goldman Sachs, with the life sciences company’s stock also added to Goldman’s “Conviction Buy” list. Goldman thinks PerkinElmer’s growth will accelerate beyond the Street’s consensus estimates.

Avaya Avaya is preparing to investigate a possible sale of the company, according to a Bloomberg report. That follows the receipt of unsolicited interest in the business communications company.

ZogenixZogenix shares are under pressure after the Food and Drug Administration refused to review a marketing application for the drugmaker’s seizure treatment. The FDA said the application was insufficient and would have to be resubmitted.

U.S. Steel The steelmaker’s stock was downgraded to underperform” from “neutral” at Credit Suisse, which points to a weakened competitive position for U.S. Steel.

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here